Design and synthesis of pinanamine derivatives as anti-influenza A M2 ion channel inhibitors
[Display omitted] ► A series of pinanamine derivatives were design and synthesized for M2 inhibitors. ► Several imidazole and guanazole substituted compounds were found to inhibit WT A/M2 as potent as amantadine. ► Compound 12 was identified to be a novel inhibitor against both A/M2-WT and A/M2-S31N...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2012-11, Vol.96 (2), p.91-99 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
► A series of pinanamine derivatives were design and synthesized for M2 inhibitors. ► Several imidazole and guanazole substituted compounds were found to inhibit WT A/M2 as potent as amantadine. ► Compound 12 was identified to be a novel inhibitor against both A/M2-WT and A/M2-S31N mutant channels.
The adamantanes are a class of anti-influenza drugs that inhibit the M2 ion channel of the influenza A virus. However recently, the clinical effectiveness of these drugs has been called into question due to the emergence of adamantane-insensitive A/M2 mutants. Although we previously reported (1R,2R,3R,5S)-3-pinanamine 3 as a novel inhibitor of the wild type influenza A virus M2 protein (WT A/M2), limited inhibition was found for adamantane-resistant M2 mutants. In this study, we explored whether newly synthesized pinanamine derivatives were capable of inhibiting WT A/M2 and selected adamantane-resistant M2 mutants. Several imidazole and guanazole derivatives of pinanamine were found to inhibit WT A/M2 to a comparable degree as amantadine and one of these compounds 12 exhibits weak inhibition of A/M2-S31N mutant and it is marginally more effective in inhibiting S31NM2 than amantadine. This study provides a new insight into the structural nature of drugs required to inhibit WT A/M2 and its mutants. |
---|---|
ISSN: | 0166-3542 1872-9096 |
DOI: | 10.1016/j.antiviral.2012.09.001 |